SEARCH

SEARCH BY CITATION

References

  • ARBAB, M.A., DELGADO, T., WIKLUND, L. & SVENDGAARD, N.A. (1988). Brain stem terminations of the trigeminal and upper spinal ganglia innervation of the cerebrovascular system: WGA-HRP transganglionic study. J. Cereb. Blood Flow Metab., 8, 5463.
  • ARUNLAKSHANA, O. & SCHILD, H.O. (1959). Some quantitative use of drug antagonists. Br. J. Pharmacol. Chemother., 257, 4858.
  • BLASCHKE, V., JUNGERMANN, K. & PUSCHEL, G.P. (1996). Exclusive expression of the Gs-linked prostaglandin E2 receptor subtype 4 mRNA in human mononuclear Jurkat and KM-3 cells and coexpression of subtype 4 and 2 mRNA in U-937 cells. FEBS Lett., 394, 3943.
  • BOIE, Y., STOCCO, R., SAWYER, N., SLIPETZ, D.M., UNGRIN, M.D., NEUSCHAFER-RUBE, F., PUSCHEL, G.P., METTERS, K.M. & ABRAMOVITZ, M. (1997). Molecular cloning and characterisation of the four rat prostaglandin EP receptor subtypes. Eur. J. Pharmacol., 340, 227241.
  • BOKU, K., OHNO, T., SAEKI, T., HAYASHI, H., HAYASHI, I., KATORI, M., MURATA, T., NARUMIYA, S., SAIGENJI, K. & MAJIMA, M. (2001). Adaptive cytoprotection mediated by prostaglandin I2 is attributed to sensitisation of CGRP-containing sensory nerves. Gastroenterology, 120, 134143.
  • BOLAY, H., REUTER, U., DUNN, A.K., HUANG, Z., BOAS, D.A. & MOSKOWITZ, M.A. (2002). Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat. Med., 8, 136142.
  • BREYER, R.M., DAVIS, L.S., NIAN, C., REHDA, R., STILLMAN, B., JACOBSON, H.R. & BREYER, M.D. (1996). Cloning and expression of the rabbit prostaglandin EP4 receptor. Am. J. Physiol., 270, F485F493.
  • BUZZI, M.G., CARTER, W.B., SHIMIZU, T., HEATH, H. & MOSKOWITZ, M.A. (1991). Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology, 30, 11931200.
  • CARLSON, L.A., EKELUND, L.G. & ORÖ, L. (1968). Clinical and metabolic effects of different doses of prostaglandin E1 in man. Prostaglandin and related factors. Acta Med. Scand., 83, 423430.
  • CODISPOTI, J.R., PRIOR, M.J., FU, M., HARTE, C.M. & NELSON, E.B. (2001). Efficacy of non-prescription doses of ibuprofen for treating migraine headache. A randomised controlled trial. Headache, 41, 665679.
  • COLEMAN, R.A., GRIX, S.P., HEAD, S.A., LOUTTIT, J.B., MALLET, A. & SHELDRICK, R.L. (1994b). A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins, 47, 151168.
  • COLEMAN, R.A., SMITH, W.L. & NARUMIYA, S. (1994a). VIII. Internation Union of Pharmacology Classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev., 46, 205229.
  • DAVIS, T.L. & SHARIF, N.A. (2000). Pharmacological characterisation of [3H]-prostaglandin E2 binding to the cloned human EP4 receptor. Br. J. Pharmacol., 130, 19191926.
  • DIB, M., MASSIOU, H., WEBER, M., HENRY, P., GARCIA-ACOSTA, S. & BOUSSER, M.G. (2002). Efficacy of oral ketoprofen in acute migraine: a double-blind randomised clinical trial. Neurology, 58, 16601665.
  • DIENER, H.C. (1999). Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomised, multicenter, parallel group study. Cephalagia, 19, 581588.
  • EBERSBERGER, A., AVERBECK, B., MESSLINGER, K. & REEH, P.W. (1999). Release of substance P, calcitonin gene-related peptide and prostaglandin E2 following electrical and chemical stimulation in vitro. Neuroscience, 89, 901907.
  • EBERSBERGER, A., SCHAIBLE, H.G., AVERBECK, B. & RICHTER, F. (2001). Is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache Ann. Neurol., 49, 713.
  • FRIESE, N., DIOP, L., CHEVALIER, E., ANGEL, F., RIVIERE, P.J. & DAHL, S.G. (1997). Involvement of prostaglandins and CGRP-dependent sensory afferents in peritoneal irritation-induced visceral pain. Regul. Pept., 70, 17.
  • GAO, I.K., SCHOLZ, P., BOEHME, M.W.J., NORDEN, C. & LEMMEL, E.-M. (2002). A 7-day oral treatment of patients with active rheumatoid arthritis using the prostacyclin analog iloprost: cytokine modulation, safety and clinical effects. Rheumatol. Int., 22, 4551.
  • GARDINER, P.J. (1986). Characterisation of prostanoid relaxant/inhibitory receptor using a highly selective agonist, TR4979. Br. J. Pharmacol., 87, 4556.
  • GOADSBY, P.J. & EDVINSSON, L. (1993). The trigeminal system and migraine: studies characterising cerebrovascular and neuropeptide changes seen in man and cat. Ann. Neurol., 33, 4856.
  • HILDEBRAND, M. (1997). Pharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patients. Eur. J. Pharmacol., 53, 5156.
  • HUA, X.Y., JINNO, S., BACK, S.M., TAM, E.K. & YAKSH, T.L. (1994). Multiple mechanisms for the effects of capsaicin, bradykinin and nicotine on CGRP release from tracheal afferent nerves: role of prostaglandins, sympathetic nerves and mast cells. Neuropharmacology, 33, 11471154.
  • HUMPHREY, P.P. & FENIUK, W. (1991). Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol. Sci., 12, 444446.
  • JENKINS, D.W., FENIUK, W. & HUMPHREY, P.P.A. (2001). Characterisation of the prostanoid receptor types involved in mediating calcitonin gene-related peptide release from cultured rat trigeminal neurones. Br. J. Pharmacol., 134, 12961302.
  • KELLSTEIN, D.E., LIPTON, R.B., GEETHA, R., KORONKIEWICZ, K., EVANS, F.T., STEWART, W.F., WILKES, K., FUREY, S.A., SUBRAMANIAN, T. & COOPER, S.A. (2000). Evaluation of a novel solubilised formulation of ibuprofen in the treatment of migraine headache: a randomised, double-blind, placebo-controlled, dose-ranging study. Cephalagia, 20, 223243.
  • KIRIYAMA, M., USHIKUBI, F., MOBAYASHI, T., HIRATA, M., SUGIMOTO, Y. & NARUMIYA, S. (1997). Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol., 122, 217224.
  • KOBARI, M., FUKUUCHI, Y., TOMITA, M., TANAHASHI, N., KONNO, S. & TAKEDA, H. (1993). Effects of sumatriptan on the cerebral intraparenchymal microcirculation in the cat. Br. J. Pharmacol., 110, 14451448.
  • LUMLEY, P., WHITE, B.P. & HUMPHREY, P.P. (1989). GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle, in vitro. Br. J. Pharmacol., 97, 783794.
  • MACHWATE, M., HARADA, S., LEU, C.T., SEEDOR, G., LABELLE, M., GALLANT, M., HUTCHIN, S., LACHANCE SAWYER, N., SLIPETZ, D., METTERS, K.M., RODAN, S.B., YOUNG, R. & RODAN, G.A. (2001). Prostaglandin receptor EP4 mediates the bone anabolic effects of PGE2. Mol. Pharmacol., 60, 3641.
  • MACHWATE, M., HARADA, S., LEU, C.T., SEEDOR, G., LABELLE, M., GALLANT, M., HUTCHIN, S., LACHANCE SAWYER, N., SLIPETZ, D., METTERS, K.M., RODAN, S.B., YOUNG, R. & RODAN, G.A. (2003). Correction to: Prostaglandin receptor EP4 mediates the bone anabolic effects of PGE2. Mol. Pharmacol., 64, 192.
  • MAY, A., BUCHEL, C., TURNER, R. & GOADSBY, P.J. (2001). Magnetic resonance angiography in facial and other pain: neurovascular mechanisms of trigeminal sensation. J. Cereb. Blood Flow Metab., 21, 11711176.
  • MOSKOWITZ, M.A. (1993). Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol. Sci., 13, 307377.
  • NAKAGOMI, T., KASSELL, N.F., SASAKI, T., LEHMAN, R.M., TORNER, J.C., HONGO, K. & LEE, J.H. (1988). Effects of removal of the endothelium on vasoconstriction in canine and rabbit basilar arteries. J. Neurosurg., 68, 757766.
  • NATTERO, G., ALLAIS, G., DE LORENZO, C., BENEDETTO, C., ZONCA, M., MELZI, E. & MASSOBRIO, M. (1989). Relevance of prostaglandins in true menstrual migraine. Headache, 29, 232237.
  • NEGISHI, M., SUGIMOTO, Y. & ICHIKAWA, A. (1995). Molecular mechanisms of diverse actions of prostanoid receptors. Biochem. Biophys. Acta, 1259, 109120.
  • OBACH TUCA, J., PLANAS, J.M. & PARELLADA, P.P. (1989). Increase in PGE2 and TXA2 in the saliva of common migraine patients. Actions of calcium channel blockers. Headache, 29, 498501.
  • PARANTAINEN, J. (1983). Prostaglandin in alcohol intolerance and hangover. Drug Alcohol Depend., 11, 239248.
  • PARSONS, A.A. & WHALLEY, E.T. (1989). Effects of prostanoids on human and rabbit basilar arteries pre-contracted in vitro. Cephalalgia, 9, 165171.
  • PEATFIELD, R.C., GAVEL, M.J. & ROSE, F.C. (1981). The effect of infused prostacyclin in migraine and cluster headache. Headache, 21, 190195.
  • PRIOR, M.J., COOPER, K.M., MAY, L.G. & BOWEN, D.L. (2002). Efficacy and safety of acetaminophen and naproxen in the treatment of tension-type headache. A randomised, double blind, placebo-controlled trial. Cephalalgia, 22, 232240.
  • RICH, G., YOBER, E.J., PROKUSKI, L. & MOORE, S.A. (1996). Prostaglandin production in cultured cerebral microvasculature smooth muscle is serum dependent. Am. J. Physiol., 270, C1379C1387.
  • SARCHIELLI, P., ALBERTI, A., CODINI, M., FLORIDI, A. & GALLAI, V. (2000). Nitric oxide metabolites, prostaglandin and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia, 20, 907918.
  • THE DICLOFENAC-K/SUMATRIPTAN MIGRAINE STUDY GROUP. (1999). Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia, 19, 232240.
  • USKI, T., ANDERSSON, K.E., BRANDT, L., EDVINSSON, L. & LIUNOGREN, B. (1983). Responses of isolated feline and human cerebral arteries to prostacyclin and some of its metabolites. J. Cereb. Blood Flow Metab., 3, 238245.
  • WHALLEY, E.T., SCHILLING, L. & WAHL, M. (1989). Cerebrovascular effects of prostanoids: in vitro studies in feline middle cerebral and basilar artery. Prostaglandins, 38, 625634.
  • WILLIAMSON, D.J., HARGREAVES, R.J., HILL, R.G. & SHEPHEARD, S.L. (1997). Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetised rat-intravital microscope studies. Cephalalgia, 17, 525531.
  • ZIMMERMANN, K., REEH, P.W. & AVERBECK, B. (2002). ATP can enhance the proton-induced CGRP release through P2Y receptors and secondary PGE2 release in isolated rat dura. Pain, 97, 259265.